Investigate the therapeutic potential of clearing senescent cells (senolytics) to slow or reverse neurodegeneration. Key questions: 1. Which senescent cell types in the brain contribute most to neurodegeneration (microglia, astrocytes, oligodendrocyte precursors)? 2. What senolytic compounds (dasatinib+quercetin, navitoclax, fisetin) show BBB penetration and CNS efficacy? 3. What is the evidence from animal models linking cellular senescence to Alzheimer's, Parkinson's, and other neurodegenerative diseases? 4. What are the risks of removing senescent cells in the aging brain (e.g., loss of SASP-mediated repair signals)? 5. What clinical trials exist or are planned for senolytics in neurodegeneration?
0
investigations
0
debates
Scores
Composite
0.704
Importance
0.880
Tractability
0.820
Novelty
0.780
Priority
0.950
Market Price
0.500